scholarly journals Impact of Chemotherapy on Acute Toxicity in Breast Cancer Patients Treated with Breast Conserving Surgery and Hypofractionated Whole Breast Irradiation: A Single Institution Experience

2017 ◽  
Vol 99 (2) ◽  
pp. E12
Author(s):  
T. Diwanji ◽  
J.Y. Lin ◽  
A. Lozano ◽  
A.M. Chhabra ◽  
J.K. Molitoris ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Acute Toxicity ◽  
Cancer Patients ◽  
Breast Conserving Surgery ◽  
Whole Breast Irradiation ◽  
Breast Irradiation ◽  
Breast Cancer Patients ◽  
Single Institution ◽  
Hypofractionated Whole Breast Irradiation

scholarly journals A comparative study on hypofractionated whole-breast irradiation with sequential or simultaneous integrated boost on different positions after breast-conserving surgery

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ting Yu ◽  
Yankang Li ◽  
Tao Sun ◽  
Min Xu ◽  
Wei Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Conserving Surgery ◽  
Simultaneous Integrated Boost ◽  
Whole Breast Irradiation ◽  
Breast Irradiation ◽  
Breast Cancer Patients ◽  
Sequential Boost ◽  
Integrated Boost ◽  
Hypofractionated Whole Breast Irradiation

AbstractThis study explored the dosimetric difference between hypofractionated whole-breast irradiation (HFWBI) with sequential boost (SEB) and simultaneous integrated boost (SIB) based on supine and prone positions to identify the superior boost mode and superior position. Thirty breast cancer patients eligible for HFWBI after breast-conserving surgery were enrolled. All patients underwent 3DCT simulation scanning in both supine and prone positions. For the SEB-HFWBI plan, the dose prescribed for the planning target volume (PTV) of whole breast (WB) was 2.67 Gy per fraction with a total of 15 fractions, followed by a sequential boost of 3.2 Gy per fraction to the PTV of tumor bed (TB) in 3 fractions. For the SIB-HFWBI plan, the dose prescribed for the PTV of WB was 2.67 Gy per fraction with a total of 15 fractions, with a simultaneously integrated boost of 3.2 Gy per fraction to the PTV of TB with a total of 15 fractions. Regardless of the position, for the PTV of TB, the conformal index (CI) in the SIB-HFWBI plans was greater than those in the SEB-HFWBI plans (T = − 8.114, − 8.114; both P < 0.05). The CI for the PTV of WB increased significantly in the prone position relative to the supine position in both two plans(Z = − 3.340, − 3.501; all P < 0.05). The study suggested that prone SIB-HFWBI might be more suitable for postoperative radiotherapy after breast-conserving surgery for early-stage breast cancer patients.

scholarly journals Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treated with breast-conserving surgery and whole breast irradiation

2017 ◽  
Vol 58 (1) ◽  
pp. 79-85 ◽  
Author(s):  
Kimiko Hirata ◽  
Michio Yoshimura ◽  
Minoru Inoue ◽  
Chikako Yamauchi ◽  
Masakazu Ogura ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Dose ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Breast Conserving Surgery ◽  
Regional Recurrence ◽  
Whole Breast Irradiation ◽  
Breast Irradiation ◽  
Breast Cancer Patients

Abstract Radiotherapy with breast-conserving therapy plays a crucial role in the treatment of early breast cancer. However, optimal radiotherapy targets have been controversial. We therefore evaluated regional recurrence in breast cancer patients with one to three positive lymph nodes (LNs) treated with breast-conserving surgery (BCS) followed by whole-breast irradiation (WBI). From 1993 to 2010, 121 breast cancer patients with one to three positive LNs who underwent BCS followed by WBI were analyzed. All patients underwent radiotherapy with two tangential fields to the whole breast. To evaluate the radiation dose to the axillary LNs, we contoured axillary LNs area and evaluated the dose–volumetric parameters. The median follow-up time was 112.4 months (range, 15.6–248.1 months). The 5-year overall survival and disease-free survival rates were 95.6% and 86.6%, respectively. The 5-year regional recurrence–free rate (RRFR) was 97.4%. During follow-up, six patients had regional recurrence. The pathological T stage was the factor best associated with the 5-year RRFR using the log-rank test, with 100.0% in the pT1 cohort versus 94.7% in the pT2–4 cohort (P &lt; 0.01). The radiation dose to the axillary LNs did not contribute to the RRFR. In conclusion, while the pathological T stage was the prognostic factor best associated with regional recurrence, few regional recurrences were observed in early breast cancer patients with one to three LNs treated with BCS followed by WBI. Unintentional radiation doses to the axillary LNs using standard WBI were not related to the RRFR after axillary dissection.

Sign in / Sign up

Export Citation Format

Share Document